Impact of safety warnings for fluoroquinolones on prescribing behaviour. Results of a cohort study with outpatient routi
- PDF / 802,111 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 94 Downloads / 145 Views
ORIGINAL PAPER
Impact of safety warnings for fluoroquinolones on prescribing behaviour. Results of a cohort study with outpatient routine data Ulrike Georgi1,2 · Falko Tesch2 · Jochen Schmitt2 · Katja de With3 Received: 12 July 2020 / Accepted: 28 October 2020 © The Author(s) 2020
Abstract Purpose The need for drug-related safety warnings is undisputed, but their impact on prescribing behaviour is not always clear. Safety warnings usually do not contain therapeutic alternatives. Based on German outpatient routine healthcare data, our cohort study investigated the impact of three warnings for fluoroquinolones on prescribing behaviour. Methods Structural breaks were estimated in a time-series analysis (2005–2014) of 184,134 first antibiotic prescriptions for patients (≥ 18 years) diagnosed with community-acquired pneumonia (CAP), acute bacterial sinusitis (ABS), or acute exacerbation of chronic bronchitis (AECB). Subsequently, risk factors for patients’ before/after safety warnings presented as risk ratios (RR) were estimated by Poisson regression. Results Following the 2008 warning for moxifloxacin, the RR of being prescribed moxifloxacin was reduced by 56% (95% CI 0.41–0.47; p
Data Loading...
